Log In Get Started
Press Releases May 28, 2026 08:00 AM

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics Announces Participation in Multiple June Investor Conferences

By Marcus Reed CRSP

CRISPR Therapeutics AG, a leader in gene editing therapies and pioneer in CRISPR/Cas9 technology, announced its senior management will participate in key investor conferences in June 2026, including Jefferies, William Blair, and Goldman Sachs events. The company highlighted its recent FDA approval of CASGEVY®, the first CRISPR-based therapy for sickle cell disease and beta thalassemia, and its expansion into various therapeutic areas such as oncology and cardiovascular disease. The disclosures aim to provide transparency and updates to investors amid continued development and partnership efforts.

CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRSP

Key Points

  • CRISPR Therapeutics management will present at three major healthcare investor conferences in June 2026, providing updates on company progress and strategic vision.
  • The company recently achieved FDA approval for CASGEVY®, the first approved CRISPR-based gene therapy, marking a significant milestone in gene editing medicine.
  • CRISPR is advancing a broad pipeline across multiple disease categories, including hemoglobinopathies, cardiovascular, autoimmune, oncology, and rare diseases, leveraging novel gene editing technologies like the SyNTase™ platform.

ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June.

Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Time: 9:55 a.m. ET

William Blair’s 46th Annual Growth Stock Conference
Date: Wednesday, June 3, 2026
Time: 4:40 p.m. CT

Goldman Sach’s 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 2:40 p.m. ET

A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

Investor Contact:
+1-617-307-7503
[email protected]

Media Contact:
+1-617-315-4493
[email protected]


Risks

  • Market and investor sentiment may be cautious due to the early-stage and complex nature of gene editing therapeutics and ongoing regulatory considerations.
  • Competition in gene editing and biopharmaceutical sectors is intense, with potential for delays or setbacks in clinical development or commercialization.
  • Partnership reliance and technology scale-up challenges, including the performance of proprietary platforms like SyNTase™, may impact future pipeline success.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026